Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer

Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of Quality of Life in Patients With Ras-wildtype Colorectal Cancer

80 - 90 % of the patients treated with anti-EGFR antibodies (panitumumab or cetuximab) experience skin toxicity, mostly acne like skin rash.

A standardized treatment of skin rash is neither established as standard arm for clinical trials nor as guideline for the treatment of skin toxicity in clinical practice. While an improvement of QoL has been demonstrated for panitumumab and cetuximab in comparison to best supportive care the data basis for patient related outcomes regarding skin toxicity deriving from randomized trials is still small.

Recent surveys among German oncologist revealed that physicians are reluctant to use oral antibiotics as preemptive treatment . Only 19 out of 110 oncologists stated that they are thinking about using preemptive treatment in patients with acne-like skin rash.

Thus, in the present trial two main questions will be addressed:

(i) Can preemptive treatment with oral doxycycline be replaced by a sequential skin treatment strategy (i.e. local treatment with erythromycin followed by doxycycline in case of inefficacy = development of acne) without compromising treatment efficacy of skin toxicity treatment? (ii) Comparison of general and skin related QoL between both treatment arms.

Inclusion Criteria:

1. Patients with wild-type RAS (KRAS and NRAS) status of metastatic colorectal cancer treatment with panitumumab according to label

   • RAS wild-type tested in
   • KRAS exon 2 (codons 12/13)
   • KRAS exon 3 (codons 59/61)
   • KRAS exon 4 (codons 117/146)
   • NRAS exon 2 (codons 12/13)
   • NRAS exon 3 (codons 59/61)
   • NRAS exon 4 (codons 117/146)

2. treatment with pre-emptive study medication shall begin the day before treatment start with panitumumab

3. Willingness to cope with biweekly quality of life questionnaires

4. Written Informed consent

5. Aged at least 18 years

6. ECOG Performance Status 0-2

7. Life expectancy of at least 12 weeks

8. Adequate haematological, hepatic, renal and metabolic function parameters:

   • Leukocytes > 3000/mm³
   • ANC ≥ 1500/mm³
   • Platelets ≥ 100,000/mm³
   • Haemoglobin > 9 g/dl
   • Serum creatinine ≤ 1.5 x ULN
   • Bilirubin ≤ 1.5 x ULN
   • GOT-GPT ≤ 2.5 x ULN (in case of liver metastases GOT / GPT ≤ 5 x ULN)
   • AP ≤ 5 x ULN
   • Magnesium, Calcium and potassium within normal ranges (may be substituted before study entry)

Exclusion criteria:

1. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
2. Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly).
3. Serious concurrent diseases
4. On-treatment participation in a clinical study in the period 30 days prior to inclusion
5. Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrolment.
6. History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
7. History of HIV infection.
8. Other previous or concurrent malignancy (≤ 5 years prior to enrolment in study) except non-melanoma skin cancer or cervical carcinoma FIGO stage 0- 1 if the patient is continuously disease-free
9. Known allergic reactions on panitumumab, doxycycline or erythromycin
10. Previous treatment with anti-cancer agents directed against EGFR (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib)
11. Skin rash existing before or due to other reasons than panitumumab treatment
12. Other dermatologic disease that may interfere with correct grading of panitumumab induced skin rash
13. Parallel treatment with anti-tumor agents other than panitumumab